Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

Exclusion criteria

• ✕. Diagnosis of peritonitis or need treatment of peritonitis
• ✕. Bowel perforation or evidence of obstruction
• ✕. Adenomatous colonic/rectal polyps that have not been removed
• ✕. Intestinal dysplasia
• ✕. Not undertaking appropriate surveillance, if indicated, for colorectal dysplasia/malignancy
• ✕. Family history of early onset colorectal cancer, established diagnosis of HNPCC pancolitis for \>8years duration without up-to-date colorectal cancer surveillance (can be performed during screening endoscopy if considered clinically appropriate by Investigator)
• ✕. An anti-TNF biologic within 8 weeks prior to randomization, unless therapeutic drug monitoring is performed, and drug concentrations are undetectable.
• ✕. Any biologic targeting immune response other than an anti-TNF (including vedolizumab and ustekinumab) within 12 weeks prior to randomization unless validated therapeutic drug monitoring is performed, and drug concentrations are indetectable. Biologics not targeting immune response (eg, denosumab) will not be contraindicated.